Skip to main content
Utility Menu
Patients
Healthcare Providers
Investors
Newsroom
Contact Us
Regional Navigation
Global Sites
Switzerland
Deutsch
English
Français
Italiano
UK
English
United States
English
Toggle Menu Button
Utility Menu
Patients
Healthcare Providers
Investors
Newsroom
Contact Us
Regional Navigation
Global Sites
Switzerland
Deutsch
English
Français
Italiano
UK
English
United States
English
Social Links
Twitter
LinkedIn
Instagram
Facebook
Main navigation
Our Disease Areas
Duchenne Muscular Dystrophy
Limb-girdle Muscular Dystrophy
Facioscapulohumeral muscular dystrophy
Myotonic dystrophy type 1
Our Science
siRNA
RNA Platform
Gene Therapy
Manufacturing
Strategic Partnerships
Investigator-Initiated Studies
Our Products & Pipeline
Products
Pipeline
Clinical Trials
Treatment Access
About Us
Leadership
Patient Affairs
Corporate Responsibility
Grants & Giving
Global Locations
Contact Us
Join Us
Career Opportunities
Toggle Menu Button
Search
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
Community Letter: Update on DM1 Clinical Development Program
Community Letter: Update on FSHD1 Clinical Development Program
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
siRNA
Facioscapulohumeral muscular dystrophy
Myotonic dystrophy type 1
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
A trusted role in Duchenne care: Meet our Duchenne Nurse Educators
Pagination
First page
« First
Previous page
‹ Previous
…
Page
29
Page
30
Page
31
Page
32
Current page
33
Page
34
Page
35
Page
36
Page
37
…
Next page
Next ›
Last page
Last »
